Compare Northrop Grumman Corporation (NOC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs TG Therapeutics Inc — how do they compare? Northrop Grumman Corporation trades at $513.84 (market cap $74.42B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Northrop Grumman Corporation is far larger — about 9× TG Therapeutics Inc's market cap, and Northrop Grumman Corporation pays a 1.79% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NOC | TGTX | |
|---|---|---|
Market Cap | $74.42B | $8.26B |
Sector | Industrials | Health |
52-Week High | $768.02 | $59.06 |
52-Week Low | $496.02 | $26.39 |
Enterprise Value | $88.65B | $8.50B |
Dividend Yield | 1.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $512.29, down 1.78% amid a bearish technical signal despite strong Q2 2026 earnings that beat estimates and a record $105 billion backlog. The stock faces margin pressures but maintains solid fundamentals with a P/E of 16.43 and ROE of 28.51%. Recent news highlights raised 2026 guidance driven by robust defense demand, though the stock's decline reflects investor concerns over cost challenges.
The outlook is mixed: bullish fundamentals and analyst consensus ($655 price target) support long-term growth, but near-term risks include execution on margin targets and technical bearishness. Investment appeal hinges on defense budget tailwinds offsetting operational headwinds.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
